Maxine, I'm so sorry to hear of your husband's diagnosis, and even more, of his (current/initial) prognosis. May I ask why his doctor thinks he has such a brief time left? They really are not always right, though I understand that they don't want to give too optimistic an answer. How extensive are the lung mets, and those in the spine. What is it about them that makes the doctor think they are so bad as to be that dire? Has he had the primary tumour out, or is that still there, along with the affected kidney, and is it too difficult to operate, or him too frail?
I am very glad to hear he is on Torisel (Temsorilimus) as this is one of the powerful new drugs (that Nice don't want us to have!). There are very definitely good results to be had from this drug, and patients can see reduction in their mets.
Yes, mRCC is incurable (at the moment!), but that does not mean it is untreatable (although Nice, again, would seem to prefer not to bother....) and it is exactly what Bob says, a question of holding on and holding out, and keeping going as long as we can. With these new drugs the jury is most definitely still out, and there are people still alive on them from the original trials (though you won't find Nice admitting that!). Obviously, everyone is different, and so much depends not just on the drug therapy - though you can be very pleased you are on one of the new ones - but on the individual patient, what their conditon is, other medical ailments etc etc.
If you husband has not yet had his primary tumour removed, it might be that Torisel will sufficiently improve his overal health, and shrink the primary as well as the mets, and so bring his primary tumour into operaable range. I have definitely heard of this aim of the Torisel treatment.
I would urge you to join the KCUK (Kidney Cancer UK) forum, as there is a wealth of experience and information there, as everyone on it has kidney cancer. I suspect most people here are also there as well, even if not active participants. There are also some excellent American RCC support sites with forums, and again, even more knowledge to share around.
You've entered a terrifying new world, and I can remember when it happened to us, earlier this year. But, little by little, you get your brain around all the complications, and hopefully start to see a way forward, little by little. It very definitely has to be good news that your husband is able to be on Torisel.
Regards, Julia
"Hi Rachel,
There has been mix up re. the petition - there is no petition - I think a patient has misconstrued an email i sent - no matter as they are not effective enough and we don't have enough time. However, the best thing you can all do is respond to the link - I know it is a scientific conundrum - however you can comment as you see fit. People could be very concise and state "we want to register our dissatisfaction to your appraisal findings..." It does not have to be complex.
To help you all here are some key points that could be raised:
1. The UK's drug guidance body, NICE, announced its preliminary decision on whether the NHS should use four new cancer drugs - bevacizumab, sorafenib, sunitinib and temsirolimus - to treat people with kidney cancer that has spread ('metastatic renal cell carcinoma').
Despite clinical evidence that these drugs can actually help, NICE has decided that they're too expensive. In essence, NICE doesn't think that these four drugs are value-for-money for the NHS.
2. The gold-standard method of testing whether a treatment works and is safe is the clinical trial - a careful look at how a new treatment compares against the treatments currently in use.
The more people enrolled on a clinical trial, and the longer it lasts, the more sure researchers can be about its results.
But only about a couple of thousand people every year are diagnosed with metastatic renal cell cancer*. And only one in ten people diagnosed with this stage of the disease is alive five years later.
So, for relatively rare diseases like this, it can take a long time to run trials large enough to gather watertight evidence about how well new treatments work.
3. Currently, the only available treatment for metastatic renal cell cancer is immunotherapy. This halts the disease's progress for just four months on average. But if people are unsuitable for immunotherapy, or it doesn't work, that's it. There's no other treatment option.
So doctors urgently need new treatments for this disease. And the four drugs NICE has rejected have shown considerable promise in clinical trials.
These four drugs are part of a new generation of cancer drugs, developed after years of painstaking research. They target key processes within the body that get hijacked when cancer develops.
Trials looking at whether these drugs can help people with metastatic renal cell cancer to live longer have had extremely encouraging results. NICE's assessment contains details of several such trials.
4. In fact, several of the trials were stopped early, to allow those people not receiving the new treatment to have it. Other trials showed that some of these drugs could stop the cancer from growing for several months more than immunotherapy alone. That doesn't seem much, but when you're trying to beat cancer, those extra months can mean a lot.
5. NICE agreed that patients tended to live longer when they were given these drugs. But they felt that the evidence wasn't sufficiently robust. And when they put the data from the trials into their computer models, they found that the drugs cost a lot (£20,000 - £35,000 per patient per year) compared to the benefit they brought patients - too much for them to recommend that the NHS prescribes these drugs.
Rachel, I need as many people as possible to contribute to the appraisal - they need to know enough is enough and I really don't think they'll read them all anyway - shocking but true - the numbers are far more important than content. So sorry for the mix up but we can still do much to change this.
Take care,
Kate"
Whatever cancer throws your way, we’re right there with you.
We’re here to provide physical, financial and emotional support.
© Macmillan Cancer Support 2024 © Macmillan Cancer Support, registered charity in England and Wales (261017), Scotland (SC039907) and the Isle of Man (604). Also operating in Northern Ireland. A company limited by guarantee, registered in England and Wales company number 2400969. Isle of Man company number 4694F. Registered office: 3rd Floor, Bronze Building, The Forge, 105 Sumner Street, London, SE1 9HZ. VAT no: 668265007